Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.
Salmeterol was granted FDA approval on 4 February 1994.
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 229
- Registration Number
- NCT01969721
- Locations
- 🇨🇿
1237.11.42004 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇩🇪1237.11.49003 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany
🇩🇪1237.11.49005 Boehringer Ingelheim Investigational Site, Hamburg, Germany
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 933
- Registration Number
- NCT01908140
- Locations
- 🇬🇧
Almirall Investigational Site, Sidcup, United Kingdom
Effects of Particle Size in Small Airways Dysfunction
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 17
- Registration Number
- NCT01892787
- Locations
- 🇬🇧
Brian Lipworth, Dundee, United Kingdom
Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 49
- Registration Number
- NCT01853787
- Locations
- 🇮🇹
: Pneumologia Riabilitativa-Fondazione Maugeri-Istituto Scientifico di Milano- IRCCS, Milano, Italy
🇮🇹Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Scienze Mediche, Università di Ferrara, Ferrara, Italy
A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Bufei granuleDrug: conventional medicine + TCMDrug: Bufeijianpi granuleDrug: Bufeiyishen granule
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Henan University of Traditional Chinese Medicine
- Target Recruit Count
- 360
- Registration Number
- NCT01836016
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
Dose Ranging Study
- Conditions
- Periumbilical Subcutaneous Adipose Tissue Reduction
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Neothetics, Inc
- Target Recruit Count
- 472
- Registration Number
- NCT01802723
- Locations
- 🇺🇸
United States, California, Santa Ana, California, United States
🇺🇸United States, North Carolina, Raleigh, North Carolina, United States
🇺🇸United States, Illinois, Chicago, Illinois, United States
Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients
- Conditions
- Asthma
- Interventions
- Radiation: Functional Respiratory ImagingDrug: Seretide EvohalerDrug: Placebo of Test productDrug: Placebo of Reference product
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- FLUIDDA nv
- Target Recruit Count
- 16
- Registration Number
- NCT01795664
- Locations
- 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium
Dose-ranging Study
- Conditions
- Abdominal Contour Defects
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Neothetics, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT01712451
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 629
- Registration Number
- NCT01636076
- Locations
- 🇹🇭
Novartis Investigative Site, Songkla, Thailand
Phase I Pharmacokinetic Study (SALBLOCK)
- Conditions
- Healthy Volunteer Study
- Interventions
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01564199
- Locations
- 🇫🇮
CRST (Clinical Research Services Turku), Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.